source
- Cyllene Therapeutics raises €33 million to pursue HSV-based gene therapy after Krystal modelCyllene Therapeutics, a French-US biotech, announced it has secured €33 million in financing. The capital will be used to develop HSV-based gene therapy programs, aiming to replicate the approach…
- Whistleblower Chris Deacon helps secure $100 million settlement against Horizon Blue Cross Blue ShieldChris Deacon, a former health‑care employee turned whistleblower, spent months reviewing legal and financial records that alleged misconduct by Horizon Blue Cross Blue Shield. The investigation le…